When repeating analyses for pathogenic variants in four additional genes (BRCA1, RAD50, MLH1, and MSH6) with weaker evidence of association with prostate cancer risk (5), the risk modifying effect of PRS was similar, albeit the associations were diminished (Supplementary Tables S16 and S17). This evidence concerns the gene BRCA1 and prostate carcinoma.